samedan logo
 
 
spacer
home > ict > autumn 2008 > the cool conundrum
PUBLICATIONS
International Clinical Trials

The Cool Conundrum

As the cold chain industry grows and becomes more stringently regulated, an increasing degree of responsibility is put on pharmaceutical manufacturers and distribution companies to ensure that products reach the patients in perfect condition. This increasing responsibility carries with it a seemingly exhaustive list of problems and pitfalls which can drastically affect the cold chain distribution process and, as a result, the product’s efficacy.

 

MEETING THE REQUIREMENTS

How do you find a cold chain solution which suits all journeys and can still be effective despite any extreme ambient temperatures? This needs to be achieved without having to design and test hundreds of different solutions for hundreds of varying destinations, whilst coping with unexpected delays. And how do you ensure the product survives to the end of the all important last mile whilst retaining its integrity? Alongside this, fulfilling your corporate social responsibility by finding an environmentally friendly solution is...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Natasha Molnár has worked for SCA Cool Logistics since January 2007 within the Commercial Team. Having qualified with an English Literature degree, and with a background in management consultancy and information technology, Natasha has marketing and management experience in both the public and private sector. As the Marketing Co-ordinator, Natasha is responsible for all aspects of the look and feel of the company including the recent rebranding exercise for the complete range of SCA Cool Logistics temperature controlled packaging products.
spacer
Natasha Molnár
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery • New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement